236 related articles for article (PubMed ID: 23525731)
1. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
[TBL] [Abstract][Full Text] [Related]
2. [Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma].
Chen AP; Zhang J; Liu H; Zhao SP; Dai SZ; Sun XL
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):48-52. PubMed ID: 19538870
[TBL] [Abstract][Full Text] [Related]
3. [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
Zhang J; Chen AP; Wang B; Zhao SP; Liu LZ; Dai SZ
Ai Zheng; 2008 Dec; 27(12):1331-6. PubMed ID: 19080004
[TBL] [Abstract][Full Text] [Related]
4. [Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].
Katsaros D; Fracchioli S; Arts HJ; de Vries EG; Danese S; Richiardi G; Arisio R; Gordini G; Van der Zee AG; Suurmeijer AJ; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):463-70. PubMed ID: 10767994
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma.
Lu D; Shi HC; Wang ZX; Gu XW; Zeng YJ
Br J Biomed Sci; 2011; 68(2):69-74. PubMed ID: 21706917
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma.
Arts HJ; Katsaros D; de Vries EG; Massobrio M; Genta F; Danese S; Arisio R; Scheper RJ; Kool M; Scheffer GL; Willemse PH; van der Zee AG; Suurmeijer AJ
Clin Cancer Res; 1999 Oct; 5(10):2798-805. PubMed ID: 10537344
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Matsuo K; Eno ML; Ahn EH; Shahzad MM; Im DD; Rosenshein NB; Sood AK
Am J Clin Oncol; 2011 Oct; 34(5):488-93. PubMed ID: 20921883
[TBL] [Abstract][Full Text] [Related]
10. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
12. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer.
Sedláková I; Laco J; Caltová K; Červinka M; Tošner J; Řezáč A; Špaček J
Int J Gynecol Cancer; 2015 Feb; 25(2):236-43. PubMed ID: 25594141
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
Mayr D; Pannekamp U; Baretton GB; Gropp M; Meier W; Flens MJ; Scheper R; Diebold J
Pathol Res Pract; 2000; 196(7):469-75. PubMed ID: 10926324
[TBL] [Abstract][Full Text] [Related]
15. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
Ricciardelli C; Lokman NA; Cheruvu S; Tan IA; Ween MP; Pyragius CE; Ruszkiewicz A; Hoffmann P; Oehler MK
Clin Exp Metastasis; 2015 Jun; 32(5):441-55. PubMed ID: 25895698
[TBL] [Abstract][Full Text] [Related]
16. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
[TBL] [Abstract][Full Text] [Related]
18. [Predictive value of drug resistance-related genes expression in neoadjuvant chemotherapy in patients with non-small cell lung cancer of stage III].
Peng ZM; Luo J; Wang WB; Wang XH; Chen JH; Lan SM
Ai Zheng; 2004 Aug; 23(8):963-7. PubMed ID: 15301725
[TBL] [Abstract][Full Text] [Related]
19. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
20. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
